Study of Effects of Vitamin D on expression of some of genes in MS patient

Study of Effects of Vitamin D on expression of TGF-ßI, TGF-ßII, TGF-ß RI, TGF-ß RII, NF?B1 and IL-10 genes in Multiple Sclerosis patient

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014011216181N1

Enrollment

Registered

2014-03-14

Start date

2012-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple sclerosis. Multiple sclerosis

Interventions

vitamin D, 50000 IU /a week , 8 weeks.

Treatment - Drugs

vitamin D, 50000 IU /a week , 8 weeks

Eligibility

Sex/Gender

All

Age

20 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: relapsing-remitting multiple sclerosis patients; MS patients with vitamin D deficiency (<80ng/ml). Exclusion criteria: patients treated with vitamin D supplements; progressive MS; relapsed patients.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Expression of IL10 gene. Timepoint: before vitamin D treatment and two month after treatment. Method of measurement: obtain of blood from patients and measurment of mRNA level.;Expression of TGF-B1 gene. Timepoint: before vitamin D treatment and two month after treatment. Method of measurement: obtain of blood from patients and measurement of mRNA level.;Expression of TGF-B2, TGF-B receptor I, TGFB receptor II, NF-KB, VDR gene. Timepoint: before vitamin D treatment and two month after treatment. Method of measurement: obtain of blood from patients and measurement of mRNA level.;Serum vitamin D. Timepoint: before vitamin D treatment and two month after treatment. Method of measurement: obtain of blood from patients and measurement of serum vitamin D level.	—

Measure

Time frame

Expression of IL10 gene. Timepoint: before vitamin D treatment and two month after treatment. Method of measurement: obtain of blood from patients and measurment of mRNA level.;Expression of TGF-B1 gene. Timepoint: before vitamin D treatment and two month after treatment. Method of measurement: obtain of blood from patients and measurement of mRNA level.;Expression of TGF-B2, TGF-B receptor I, TGFB receptor II, NF-KB, VDR gene. Timepoint: before vitamin D treatment and two month after treatment. Method of measurement: obtain of blood from patients and measurement of mRNA level.;Serum vitamin D. Timepoint: before vitamin D treatment and two month after treatment. Method of measurement: obtain of blood from patients and measurement of serum vitamin D level.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrdad Behmanesh

Tarbiat Modares University of Tehran

behmanesh@modares.ac.ir+98 21 8288 4451

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026